Marie K Langberg1, Carina Berglund-Nord2, Gabriella Cohn-Cedermark2, Hege S Haugnes3, Torgrim Tandstad4, Carl W Langberg5. 1. a Faculty of Medicine , University of Oslo , Oslo , Norway. 2. b Department of Oncology-Pathology , Karolinska University Hospital and Karolinska Institutet , Stockholm , Sweden. 3. c Institute of Clinical Medicine - Oncology , University of Tromsø and University Hospital of North Norway , Tromsø , Norway. 4. d The Cancer Clinic , St. Olavs Hospital , Trondheim , Norway. 5. e Department of Oncology , University Hospital of Oslo , Oslo , Norway.
Abstract
BACKGROUND: An increasing number of anticancer drugs have been reported to cause pneumonitis. Chemotherapy-induced pneumonitis may cause severe morbidity and event death. As there has been a lack of effective treatment, new treatment strategies are needed. A previous case report has indicated that imatinib may be useful. PATIENT AND METHODS: The SWENOTECA experience of four cases with severe life-threatening chemotherapy-induced pneumonitis treated with imatinib is presented. RESULTS: All four patients responded to treatment with imatinib. CONCLUSIONS: Imatinib appears to be an effective treatment of severe chemotherapy-induced pneumonitis in germ cell cancer patients.
BACKGROUND: An increasing number of anticancer drugs have been reported to cause pneumonitis. Chemotherapy-induced pneumonitis may cause severe morbidity and event death. As there has been a lack of effective treatment, new treatment strategies are needed. A previous case report has indicated that imatinib may be useful. PATIENT AND METHODS: The SWENOTECA experience of four cases with severe life-threatening chemotherapy-induced pneumonitis treated with imatinib is presented. RESULTS: All four patients responded to treatment with imatinib. CONCLUSIONS:Imatinib appears to be an effective treatment of severe chemotherapy-induced pneumonitis in germ cell cancerpatients.
Authors: Leila Atmowihardjo; Job R Schippers; Imke H Bartelink; Pierre M Bet; Nienke van Rein; Keith Purdy; David Cavalla; Valérie Comberiati; Andrew McElroy; Sue D Snape; Harm Jan Bogaard; Leo Heunks; Nicole Juffermans; Marcus Schultz; Pieter R Tuinman; Lieuwe D J Bos; Jurjan Aman Journal: Trials Date: 2022-02-16 Impact factor: 2.279
Authors: Jurjan Aman; Erik Duijvelaar; Liza Botros; Azar Kianzad; Job R Schippers; Patrick J Smeele; Sara Azhang; Imke H Bartelink; Ahmed A Bayoumy; Pierre M Bet; Wim Boersma; Peter I Bonta; Karin A T Boomars; Lieuwe D J Bos; Job J M H van Bragt; Gert-Jan Braunstahl; Lucas R Celant; Katrien A B Eger; J J Miranda Geelhoed; Yurika L E van Glabbeek; Hans P Grotjohan; Laura A Hagens; Chris M Happe; Boaz D Hazes; Leo M A Heunks; Michel van den Heuvel; Wouter Hoefsloot; Rianne J A Hoek; Romke Hoekstra; Herman M A Hofstee; Nicole P Juffermans; E Marleen Kemper; Renate Kos; Peter W A Kunst; Ariana Lammers; Ivo van der Lee; E Laurien van der Lee; Anke-Hilse Maitland-van der Zee; Pearl F M Mau Asam; Adinda Mieras; Mirte Muller; Liesbeth Neefjes; Esther J Nossent; Laurien M A Oswald; Maria J Overbeek; Carolina Pamplona; Nienke Paternotte; Niels Pronk; Michiel A de Raaf; Bas F M van Raaij; Merlijn Reijrink; Marcus J Schultz; Ary Serpa Neto; Elise M Slob; Frank W J M Smeenk; Marry R Smit; A Josien Smits; Janneke E Stalenhoef; Pieter R Tuinman; Arthur L E M Vanhove; Jessie N Wessels; Jessie C C van Wezenbeek; Anton Vonk Noordegraaf; Frances S de Man; Harm J Bogaard Journal: Lancet Respir Med Date: 2021-06-17 Impact factor: 30.700